RVL Pharmaceuticals plc (OSMT)
Price:
1.11 USD
( - -0.02 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Regeneron Pharmaceuticals, Inc.
VALUE SCORE:
6
2nd position
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
The best
Agios Pharmaceuticals, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
NEWS
Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
benzinga.com
2022-01-19 10:53:46Osmotica Pharmaceuticals plc (NASDAQ: OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ: RVLP). The Company says that the rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics.
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
globenewswire.com
2022-01-18 06:50:00-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
globenewswire.com
2021-12-20 16:05:00BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-15 21:01:02Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
zacks.com
2021-11-15 20:01:08Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
globenewswire.com
2021-11-15 06:50:00BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows:
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
globenewswire.com
2021-10-13 16:46:00BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company granted the underwriter a 30-day option to purchase up to an additional 2,100,000 ordinary shares and/or warrants to purchase additional 2,100,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. On October 11, 2021 the underwriter exercised its option to purchase additional warrants to purchase up to 2,100,000 ordinary shares.
OSMT Stock: Why It Fell By Over 35% This Week
pulse2.com
2021-10-09 11:33:40The stock price of Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) fell by over 35% this past week. This is why it happened.
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
invezz.com
2021-10-07 11:10:59Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to generate $35 million in gross proceeds from the offering Osmotica priced its previously announced public offering at $2.50 a share that represents an about […] The post Here's why Osmotica Pharmaceuticals is down 35% on Thursday appeared first on Invezz.
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
globenewswire.com
2021-10-07 09:04:00BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management (“Athyrium”).
OSMT Stock: Why It Substantially Fell Today
pulse2.com
2021-10-07 08:05:26The stock price of Osmotica Pharmaceuticals (NASDAQ: OSMT) fell by over 40% pre-market today. This is why it happened.
Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering
globenewswire.com
2021-10-07 00:31:00BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to additional 2,100,000 ordinary shares and/or additional warrants to purchase up to 2,100,000 ordinary shares, at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions.
Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering
globenewswire.com
2021-10-06 16:26:00BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares. In addition, Osmotica expects to grant the underwriter of the offering a 30-day option to purchase additional ordinary shares and/or warrants to purchase ordinary shares (equal to 15% of the ordinary shares and/or 15% of the warrants offered in the public offering) at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021
globenewswire.com
2021-09-22 17:00:00BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference
globenewswire.com
2021-09-02 17:00:00BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows:
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
globenewswire.com
2021-08-30 06:50:00-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt --
No data to display
Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
benzinga.com
2022-01-19 10:53:46Osmotica Pharmaceuticals plc (NASDAQ: OSMT) will change its name to RVL Pharmaceuticals plc and start trading under the new ticker (NASDAQ: RVLP). The Company says that the rebranding reflects RVL's strategy to become a growth company in eye care and medical aesthetics.
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
globenewswire.com
2022-01-18 06:50:00-- Topics include corporate name change, launch plans into the medical aesthetics market and general business updates -- -- Featured speakers include Dr. Jackie Yee and Dr. Justin Harper --
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
globenewswire.com
2021-12-20 16:05:00BRIDGEWATER, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows:
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
seekingalpha.com
2021-11-15 21:01:02Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
zacks.com
2021-11-15 20:01:08Osmotica Pharmaceuticals (OSMT) delivered earnings and revenue surprises of -16.67% and -7.96%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
globenewswire.com
2021-11-15 06:50:00BRIDGEWATER, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Jefferies London Virtual Healthcare Conference 2021 as follows:
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
globenewswire.com
2021-10-13 16:46:00BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares, at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company granted the underwriter a 30-day option to purchase up to an additional 2,100,000 ordinary shares and/or warrants to purchase additional 2,100,000 ordinary shares at the public offering price, less the underwriting discounts and commissions. On October 11, 2021 the underwriter exercised its option to purchase additional warrants to purchase up to 2,100,000 ordinary shares.
OSMT Stock: Why It Fell By Over 35% This Week
pulse2.com
2021-10-09 11:33:40The stock price of Osmotica Pharmaceuticals PLC (NASDAQ: OSMT) fell by over 35% this past week. This is why it happened.
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
invezz.com
2021-10-07 11:10:59Shares of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) tanked more than 35% on Thursday as the company priced its underwritten public offering of 14 million ordinary shares at a discount. Osmotica to generate $35 million in gross proceeds from the offering Osmotica priced its previously announced public offering at $2.50 a share that represents an about […] The post Here's why Osmotica Pharmaceuticals is down 35% on Thursday appeared first on Invezz.
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
globenewswire.com
2021-10-07 09:04:00BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by Athyrium Capital Management (“Athyrium”).
OSMT Stock: Why It Substantially Fell Today
pulse2.com
2021-10-07 08:05:26The stock price of Osmotica Pharmaceuticals (NASDAQ: OSMT) fell by over 40% pre-market today. This is why it happened.
Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering
globenewswire.com
2021-10-07 00:31:00BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and warrants to purchase up to 14,000,000 ordinary shares at a public offering price of $2.50 per share and accompanying warrant. The warrants have an exercise price of $3.10 per share, are immediately exercisable and will expire three and one-half years from the date of issuance. The Company has granted the underwriter a 30-day option to purchase up to additional 2,100,000 ordinary shares and/or additional warrants to purchase up to 2,100,000 ordinary shares, at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions.
Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering
globenewswire.com
2021-10-06 16:26:00BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary shares. In addition, Osmotica expects to grant the underwriter of the offering a 30-day option to purchase additional ordinary shares and/or warrants to purchase ordinary shares (equal to 15% of the ordinary shares and/or 15% of the warrants offered in the public offering) at the public offering price per share and per warrant, respectively, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021
globenewswire.com
2021-09-22 17:00:00BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference
globenewswire.com
2021-09-02 17:00:00BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows:
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
globenewswire.com
2021-08-30 06:50:00-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt --